NCT01494506 Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer Status COMPLETED Phase PHASE3
NCT01494363 Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Status UNKNOWN Phase PHASE2
NCT01490866 A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) Status COMPLETED Phase PHASE2
NCT01479465 Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma Status TERMINATED Phase PHASE2
NCT01467115 Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer Status COMPLETED Phase PHASE2
NCT01418222 FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer Status COMPLETED Phase PHASE2
NCT01413022 FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Status COMPLETED Phase PHASE1
NCT01374425 Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) Status COMPLETED Phase PHASE2
NCT01362374 Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT01308086 Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer Status UNKNOWN Phase PHASE3
NCT01302613 Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma Status WITHDRAWN Phase PHASE1/PHASE2
NCT01274624 Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer Status COMPLETED Phase PHASE1
NCT01263171 Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery Status COMPLETED Phase PHASE2
NCT01258634 A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response Status TERMINATED Phase PHASE1
NCT01246960 A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer Status COMPLETED Phase PHASE2
NCT01231802 Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer Status UNKNOWN Phase PHASE2
NCT01227707 A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer. Status COMPLETED Phase PHASE2
NCT01226719 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only Status COMPLETED Phase PHASE2
NCT01216644 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer Status COMPLETED Phase PHASE2/PHASE3